32 results about "Intracellular signaling pathways" patented technology

The present invention relates to compositions and methods comprising peptides with high mutual affinity that, when attached to a protein, assist the protein to fold into a compact structure. By virtue of its stability and binding, this scaffold extends the activity of any contained protein sequence in the presence of cellular and other proteases. This compact structure may have other included functional sequences, which are superior to linear and less constrained peptides for library screening, building structure-biased peptide libraries, and targeting specific intracellular and extracellular compartments. The compositions of the present invention can be displayed on viral, archaeal, prokaryotic and eukaryotic cell surfaces for library screening, drug screening and display. The methods of the present invention are useful for in vivo screening of intracellular effector proteins that modulate signaling pathways, and for identification of interacting proteins in vitro. Therefore, the present invention can be used as a scaffold for gene therapy, for the isolation of new therapeutic drugs, and has potential utilization value for use as a therapeutic agent in physiological fluids.

The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-dependent kinase 5 (Cdk5), AMPA receptors, protein phosphatase-1 (PP-1), protein phosphatase 2C (PP2C), protein phosphatase 2B (PP2B) and / or protein phosphatase 2A (PP2A) in cells or tissues. The invention provides methods of treating serotonergic intracellular signaling pathway disorders, e.g., depression. The invention provides methods of treating dopamine-related disorders. The invention provides methods of identifying agents that modulate the activities of serotonergic receptor intracellular signaling molecules, DARPP-32, casein kinase 1, cyclin-dependent kinase 5, AMPA receptors, protein phosphatase-1, protein phosphatase 2C, protein phosphatase 2B and / or protein phosphatase 2A, for use in such treatments. The invention also provides methods of modulating phosphorylation-dependent activation of AMPA receptors for use in such treatments.

The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.

Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway.

The invention discloses a natural immune receptor TLR5S gene of Saddletail grouper and application of a protein encoded with the natural immune receptor TLR5S gene in the aspects of identifying bacterial flagellum, regulating intracellular signal pathways and adjusting inflammatory factors. The natural immune receptor TLR5S gene has the advantages of being beneficial for knowing pathogenic microorganisms resistant to a fish body and even a physiological process of vibrio invasion and providing a scientific evidence and a practice foundation for studies on fish immunology, prevention of diseases and the like in production application. Additionally, the natural immune receptor TLR5S gene can be prepared into a drug with an effect of resisting the multiplication of vibrio patahaemolyticus inthe production application, and the natural immune receptor TLR5S gene can also be applied as an immunopotentiator.

Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway.

The present invention provides systems, methods and software for analysis of the intracellular signaling pathway activation (SPA), the method including analyzing activator and repressor roles of a plurality of gene expression gene products in a plurality of pathways in a sample of a subject to determine a pathway activation strength (PAS) for each of the plurality of pathways and comparing the pathway activation strength (PAS) in at least one sick subject with at least one healthy subject to determine intracellular signaling pathway activation (SPA) associated with a disease or disorder in the at least one sick subject.

The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.

The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK / STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK / STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and / or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog therof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK AND / or STAT3 inhibition and anti-tumor activity.

The invention provides a method for regulating cell pathway by using plant hormone GA and small molecular substance PAC, and realizes the regulation switch of signal pathway in human cells. The GA receptor proteins GID1 and GAI in Arabidopsis thaliana were constructed on a human cell expression vector, and then transferred into HEK293T cells together. GA was added to induce the interaction between the two proteins. After adding the inhibitor PAC, the degree of interaction would be weakened. In this way, the key proteins in the human cell signaling pathway are fused and expressed with these two receptor proteins. The two receptor proteins interact under the induction of GA, and the fusion signaling pathway is also induced by GA. The present invention selects the key protein LRP6 on the human Wnt pathway. After the fusion expression of GA receptor and LRP6, LRP6 will aggregate under the induction of GA, thereby promoting the production of β-catenin and opening the intracellular signaling pathway. After adding PAC inhibition, the production of β-catenin is reduced and the cell pathway is closed.

The present invention relates preferably to the use of 4-bromo-N-[(E)-(2-methyl-1H-indol-3-yl)methyleneamino]benzenesulphonamide and 4-methyl-3-oxo-2-(3-pyridylmethylene) benzo[3,4-b]furan-6-yl-4-chlorobenzenesulphonate (compounds 5 and 6, respectively), which are compounds that can inhibit the toxic activity of sphingomyelinase D from Loxosceles venom, controlling the development of cutaneous and systemic loxoscelism; reducing haemolysis; inhibiting the formation of skin lesions; inhibiting skin necrosis; inhibiting intracellular signaling pathways and the production of reactive oxygen species. In addition to the therapeutic potential thereof, said inhibitors can be used to study the activity of sphingomyelinases and phospholipases D. The present invention also relates to a pharmaceutical composition for treating loxoscelism, reducing haemolysis, inhibiting the formation of skin lesions, inhibiting skin necrosis, inhibiting intracellular signaling pathways and the production of reactive oxygen species, comprising said compounds and a pharmaceutically acceptable carrier.

Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as Parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed. An alternative approach such as viral construct transduction may be used to directly activate the intracellular signaling pathways that mediate neurotrophic effects and induce axon growth. Viral construct transduction of dopaminergic neurons with a constitutively active human form of the p70S6K gene—hp70S6K (CA)—was shown to induce axon regeneration from living dopaminergic cell bodies that had no living axons.

The present invention relates to the application of compounds inhibiting Htr3a and its downstream intracellular signaling pathways in the preparation of medicines for treating and / or preventing Alzheimer's disease. The present invention finds for the first time that the expression of Htr3a in Alzheimer's disease transgenic AD animals and AD patients is significantly increased, and the intracellular calcium (Ca 2+ ) and its downstream calcineurin activity (CaN) and transcription factor (NFAT) were significantly increased. In AD transgenic mice, inhibiting the function of Htr3a significantly reduces the production of Aβ-amyloid protein and reverses the intracellular signaling pathway Ca 2+ , CaN, and the transcription factor NFAT inhibited glial cell activation and reduced neuroinflammation. The present invention considers for the first time that Htr3a and its intracellular signaling pathway play an important role in the generation of β-amyloid plaques in AD, and regulating this pathway can prevent the progressive development of AD. Therefore, drugs targeting this pathway can prevent the process of AD, slow down the development of AD, and have great research and application prospects in the treatment of AD.

An object of the present invention is to provide a method for determination or evaluation of an extract from inflamed tissues inoculated with vaccinia virus where the enhancement of activation of neurotrophic factor such as BDNF in cultured cells or the enhancement of activation of proteins participating therein is used as an indicator. The present invention relates to a novel method for determination or evaluation of an extract from inflamed tissues inoculated with vaccinia virus and relates to a method for determination or evaluation of the extract where the enhancement of production of neurotrophic factor such as BDNF in cultured cells or the enhancement of activation of various proteins in intracellular signaling pathway participating in production of BDNF, etc. is used as an indicator. The present invention is highly useful as a simple, convenient and quick method for determination or evaluation for guaranteeing the quality of the extract which is useful as a pharmaceutical agent.

The invention belongs to the technical field of antiviral drugs, and discloses a drug for preventing or treating hepatitis B virus infection and a preparation method, wherein an overexpression plasmid or small interfering RNA of SOX9 is co-transformed with a plasmid pHBV1.3 capable of expressing HBV Transfect into the liver cell line HepG2 or Huh7; detect the expression levels of HBV secreted antigens HBeAg and HBsAg in the cell culture supernatant and the level of HBV replication intermediate nucleocapsid-related DNA in the cells. Human SOX9 provided by the present invention is a cytokine expressed constitutively in the human body, and has no toxic and side effects on the human body at physiological concentrations; human SOX9 directly acts on the virus envelope, or affects virus adsorption, or changes intracellular signaling pathways , so as to resist viruses, because of its diversified anti-virus mechanisms, it is not easy for viruses to develop drug resistance.